SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Sharck Soup
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sharck who wrote (21119)5/8/2001 8:06:41 AM
From: 2MAR$  Read Replies (2) of 37746
 
BGEN Stock Hurt by Competing MS Drug Data

Boston, May 08, 2001 (Midnight Trader via COMTEX) -- Biogen is trading lower
today on 5,100 Instinet shares after Reuters reported that Zurich-based Serono
SA released data that said its multiple sclerosis drug was more effective than
Biogen's product. The U.S. FDA has yet to approve Serono's product for use in
the states. Serono is advancing 0.59 to 23.50 on Instinet.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News